Adipose tissue and the metabolic syndrome: focusing on adiponectin and several novel adipokines.
The metabolic syndrome represents a cluster of metabolic risk factors that predispose an individual to an increased risk for Type 2 diabetes, cardiovascular diseases and their associated morbidity and mortality. Visceral obesity is thought to be a major culprit. Adipokines secreted from the adipose tissue are now believed to be key factors mediating the metabolic and inflammatory effects of obesity. In this review, we shall examine the evidence suggesting that several novel adipokines, adiponectin, adipocyte fatty acid-binding protein, retinol-binding protein-4 and lipocalin-2, may hold promise as important clinical biomarkers to identify individuals at risk for the metabolic syndrome and related comorbidities.